THE GREAT PEPTIDE DEBATE: FULL DISCUSSION Peptide bear @MartinShkreli squared off against peptide bull @maxmarchione today in a back and forth on retatrutide, BPC-157, randomized controlled trials, the FDA, the pharmaceutical industry, and more. 00:00 Opening arguments 06:08 Martin on the downsides of retatrutide 10:24 Back and forth on BPC-157 14:41 Randomized controlled trials — issues and benefits 19:19 Max on the potential of Thymosin Alpha-1 23:21 Martin on why peptides should be controlled substances 26:07 The FDA's strengths and weaknesses 29:05 Closing arguments